1. Medical jargon is often described as the second language of healthcare professionals. [2] The authors agree that varied terminologies can add to the existing confusion. They thereby prefer to adhere to the existing nomenclature pending consensus Clinical resistance is defined as the failure to eradicate a fungal infection despite the administration of an antifungal agent with in vitro activity against the organism. Clinical resistance depends on various host and drug-related factors. [1] A knowledge of distinction between clinical and microbiological resistance is required for various causative factors and their therapeutic outcome. 2. Ciclopirox olamine is approved as a topical formulation for superficial mycoses. Studies have shown that itraconazole and terbinafine have a lower minimum inhibitory concentration (MIC) than ciclopirox against Trichophyton rubrum and Trichophyton mentagrophytes. [3] Susceptibility tests on Candida albicans revealed a lower MIC for itraconazole and ketoconazole when compared to ciclopirox [4] Antimicrobial drug resistance is an almost inevitable process that is universal in the microbial world. [1] Ciclopirox also induces change in expression of genes encoding multidrug resistance efflux pumps CDR1 and CDR2. [5] Considering the above facts and the present nature of dermatophytosis, excessive reliance on any single topical medication for therapeutic goals may be unwarranted. 3. The author highlighted the fungicide usage in agriculture and azole-resistant filamentous fungi in Indian settings. 4. The main focus of our article remained the mechanism of antifungal resistance in dermatology and broad therapeutic outlines. A comprehensive review of antifungal resistance was beyond the scope of the article.
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There are no conflicts of interest. Sir, Talaromycosis (penicilliosis) is an opportunistic fungal infection seen in immunocompromised setting. Talaromyces marneffei (T. marneffei) was first isolated from bamboo rat's liver. Disseminated talaromycosis was first reported in 1988 in a 61-year-old HIV-infected American missionary. [1] Number of cases of talaromycosis have been reported from Manipur, India, but very few cases have been reported from Assam, a neighboring state of Manipur. [2] We, hereby, report a case of classical disseminated talaromycosis from Silchar, a district located in South Assam. A 39-year-old female patient presented to us with moderate intermittent fever, dry cough, and skin lesions distributed mainly over the face for 8 days. Her husband was a truck driver who was HIV positive and died 2 years back due to the chest infection. On examination, there were multiple lesions on the face with different morphologies such as vesicles, papules, and nodules interspersed with hemorrhagic and crusted lesions [ Figure 1 ]. Few lesions were also present over the trunk and upper limbs. In addition, the patient also had oral and vaginal candidiasis. On the first impression, it was thought to be hemorrhagic varicella in an immunocompromised individual. Hence, she was given intravenous acyclovir. However, no significant improvement was noted even after 5 days of treatment. Laboratory investigation showed HIV positivity with CD4 T cell count 62/µL. Her chest X-ray revealed bilateral diffuse reticulonodular opacities with prominent bronchovascular markings. Differential diagnosis such as histoplasmosis, talaromycosis, and cryptococcosis were considered. For confirmation of diagnosis, skin biopsy, and fungal culture in Sabouraud's dextrose agar (SDA) was carried out. Biopsy revealed multiple fungal elements with nonbudding yeast cell having transverse septum [ Figure 2 ]. SDA culture showed flat, glabrous, moist, and radially folded colonies. After 5 days of incubation at 25°C, a diffusible red pigment was found around the colonies [ Figure 3 ]. Fungal mycelia were clearly seen in microscopy after lactophenol cotton blue staining [ Figure 4 ]. All these features confirmed the diagnosis of talaromycosis. Administration of anti-retroviral therapy (ART) and amphotericin B, resulted in significant clinical and radiological improvement in 2 weeks. The patient was discharged with oral itraconazole 400 mg/day. Unfortunately, the patient did not turn up for follow-up. T. marneffei, the etiological fungus of talaromycosis is transmitted to human through inhalation of spores from soil. It then spreads to the reticuloendothelial system, skin and other organ system through the hematogenous route.
Talaromycosis (Penicilliosis
Cutaneous manifestations may mimic histoplasmosis, having mucocutaneous papules with central umbilication; ulceration, and lymphadenopathy may also be seen. It may precipitate Sweet's syndrome, erythema nodosum, and exanthematous pustulosis. It can be misdiagnosed as pulmonary tuberculosis, melioidosis, cryptococcosis, and leishmaniasis. [3] Sample from skin lesions, blood, or bone marrow may show characteristic nonbudding yeast cell with transverse septum. Definitive diagnosis can be made with culture from the lesional specimen.
In a study, Raju et al. described how cutaneous manifestations correlated with CD4 count. [4] These infections may also appear after starting ART, as a manifestation of immune reconstitution inflammatory syndrome. [5] T. marneffei can affect persons with normal immunity also, but it is very rare and quite reasonably it produces mild localized infection. [6] As the prognosis and severity depend on the patient's Reports of talaromycosis are quite infrequent, especially of cases that are diagnosed and confirmed on the basis of histopathology, with special stains and culture. We, thus report one such case with all supporting evidence.
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